|
1
|
Karumanchi SA, Merchan J and Sukhatme VP:
Renal cancer: molecular mechanisms and newer therapeutic options.
Curr Opin Nephrol Hypertens. 11:37–42. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Janzen NK, Kim HL, Figlin RA and
Belldegrun AS: Surveillance after radical or partial nephrectomy
for localized renal cell carcinoma and management of recurrent
disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Koul H, Huh JS, Rove KO, Crompton L, Koul
S, Meacham RB and Kim FJ: Molecular aspects of renal cell
carcinoma: a review. Am J Cancer Res. 1:240–254. 2011.PubMed/NCBI
|
|
4
|
Hadoux J, Vignot S and De La Motte Rouge
T: Renal cell carcinoma: focus on safety and efficacy of
temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Huang Y, Dai Y, Yang J, Chen T, Yin Y,
Tang M, Hu C and Zhang L: Microarray analisis of microRNA
expression in renal cell carcinoma. Eur J Surg Oncol. 35:1119–1123.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Motzer RJ, Bander NH and Nanus DM:
Renal-cell carcinoma. N Engl J Med. 335:865–875. 1996. View Article : Google Scholar
|
|
7
|
Motzer RJ, Aqarwal N, Beard C, Bhayani S,
Bolger GB, Carducci MA, Chang SS, Choueiri TK, Hancock SL, Hudes
GR, Jonasch E, Josephson D, Kuzel TM, Lavine EG, Lin DW, Margolin
KA, Michaelson MD, Olencki T, Pili R, Ratliff TW, Redman BG,
Robertson CN, Ryan CJ, Sheinfeld J, Spiess PE, Wang J and Wilder
RB: Kidney cancer. J Natl Compr Canc Netw. 9:960–977.
2011.PubMed/NCBI
|
|
8
|
Agarwala SS and Case S: Everolimus
(RAD001) in the treatment of advanced renal cell carcinoma: a
review. Oncologist. 15:236–245. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Fillipowicz W, Bhattacharyya SN and
Sonenberg N: Mechanisms of post-transcriptional regulation by
microRNAs: are the answers in sight? Nat Rev Genet. 9:102–114.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nelson KM and Weiss GJ: MicroRNAs and
cancer: past, present, and potential future. Mol Cancer Ther.
7:3655–3660. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Esquela-Kerscher A and Slack FJ:
OncomiRs-microRNAs with a role in cancer. Nat Rev Cancer.
6:259–269. 2006. View Article : Google Scholar
|
|
12
|
Hidaka H, Seki N, Yoshino H, Yamasaki T,
Yamada Y, Nohata N, Fuse M, Nakagawa M and Enokida H: Tumor
suppressive microRNA-1285 regulates novel molecular targets:
Aberrant expression and functional significance in renal cell
carcinoma. Oncotarget. 3:44–57. 2012.PubMed/NCBI
|
|
13
|
Chiyomaru T, Enokida H, Tatarano S,
Kawahara K, Uchida Y, Nishiyama K, Fujimura L, Kikkawa N, Seki N
and Nakagawa M: miR-145 and miR-133a function as tumour suppressors
and directly regulate FSCN1 expression in bladder cancer. Br J
Cancer. 102:883–891. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yoshino H, Chiyomaru T, Enokida H,
Kawakami K, Tatarano S, Nishiyama K, Nohata N, Seki N and Nakagawa
M: The tumoursuppressive function of miR-1 and miR-133a targeting
TAGLN2 in bladder cancer. Br J Cancer. 104:808–818. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kojima S, Chiyomaru T, Kawakami K, Yoshino
H, Enokida H, Nohata N, Fuse M, Ichikawa T, Naya Y, Nakagawa M and
Seki N: Tumour suppressors miR-1 and miR-133a target the oncogenic
function of purine nucleoside phosphorylase (PNP) in prostate
cancer. Br J Cancer. 106:405–413. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Nohata N, Hanazawa T, Kikkawa N, Sakurai
D, Fujimura L, Chiyomaru T, Kawakami K, Yoshino H, Enokida H,
Nakagawa M, Katayama A, Harabuchi Y, Okamoto T and Seki N: Tumor
suppressive microRNA-874 regulates novel cancer networks in
maxillary sinus squamous cell carcinoma. Br J Cancer. 105:833–841.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Kikkawa N, Hanazawa T, Fujimura L, Nohata
N, Suzuki H, Chazono H, Sakurai D, Horiguchi S, Okamoto Y and Seki
N: miR-489 is a tumour-suppressive miRNA target PTPN11 in
hypopharyngeal squamous cell carcinoma (HSCC). Br J Cancer.
103:877–884. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Yamasaki T, Yoshino H, Enokida H, Hidaka
H, Chiyomaru T, Nohata N, Kinoshita T, Fuse M, Seki N and Nakagawa
M: Novel molecular targets regulated by tumor suppressors
microRNA-1 and microRNA-133a in bladder cancer. Int J Oncol.
40:1821–1830. 2012.PubMed/NCBI
|
|
19
|
Mitomo S, Maesawa C, Ogasawara S, Iwaya T,
Shibazaki M, Yashima-Abo A, Kotani K, Oikawa H, Sakurai E, Izutsu
N, Kato K, Komatsu H, Ikeda K, Wakabayashi G and Masuda T:
Downregulation of miR-138 is associated with overexpression of
human telomerase reverse transcriptase protein in human anaplastic
thyroid carcinoma cell lines. Cancer Sci. 99:280–286. 2008.
View Article : Google Scholar
|
|
20
|
Seike M, Goto A, Okano T, Bowman ED,
Schetter AJ, Horikawa I, Mathe EA, Jen J, Yang P, Sugimura H, Gemma
A, Kudoh S, Croce CM and Harris CC: MiR-21 is an EGFR-regulated
anti-apoptotic factor in lung cancer in never-smokers. Proc Natl
Acad Sci USA. 106:12085–12090. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Satelli A and Li S: Vimentin in cancer and
its potential as a molecular target for cancer therapy. Cell Mol
Life Sci. 68:3033–3046. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Sobin LH and Wittekind C: TNM
classification of malignant tumours In: International Union Against
Cancer (UICC). 6th edition. John Wiley & Sons; Hoboken, NJ: pp.
255–257. 2009
|
|
23
|
Nohata N, Hanazawa T, Kikkawa N, Mutallip
M, Fujimaru L, Yoshino H, Kawakami K, Chiyomaru T, Enokida H,
Nakagawa M, Okamoto T and Seki N: Caveolin-1 mediates tumor cell
migration and invasion and its regulation by miR-133a in head and
neck squamous cell carcinoma. Int J Oncol. 38:209–217.
2011.PubMed/NCBI
|
|
24
|
Nohata N, Sone Y, Hanazawa T, Fuse M,
Kikkawa N, Yoshino H, Chiyomaru T, Kawakami K, Enokida H, Nakagawa
M, Shozu M, Okamoto T and Seki N: miR-1 as a tumor suppressive
microRNA targeting TAGLN2 in head and neck squamous cell carcinoma.
Oncotarget. 2:29–44. 2011.PubMed/NCBI
|
|
25
|
Siegel R, Naishadham D and Jemal A: Cancer
statistics, 2012. CA Cancer J Clin. 62:10–29. 2012. View Article : Google Scholar
|
|
26
|
Friedl P and Alexander S: Cancer invasion
and the microenvironment: plasticity and reciprocity. Cell.
147:992–1009. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Soini Y: Tight junctions in lung cancer
and lung metastasis: a review. Int J Clin Exp Pathol. 5:126–136.
2012.PubMed/NCBI
|
|
28
|
Brabletz S and Brabletz T: The ZEB/miR-200
feedback loop - a motor of cellular plasticity in development and
cancer? EMBO Rep. 11:670–677. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Mongroo PS and Rustgi AK: The role of the
miR-200 family in epithelial-mesenchymal transition. Cancer Biol
Ther. 10:219–222. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li X, Jiang L, Wang A, Yu J, Shi F and
Zhou X: MicroRNA-138 suppresses invasion and promotes apoptosis in
head and neck squamous cell lines. Cancer Lett. 286:217–222. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hogg RP, Honorio S, Martinez A,
Agathanggelou A, Dallol A, Fullwood P, Weichselbaum R, Kuo MJ,
Maher ER and Latif F: Frequent 3p allele loss and epigenetic
inactivation of the RASSF1A tumour suppressor gene from region
3p21.3 in head and neck squamous cell carcinoma. Eur J Cancer.
38:1585–1592. 2002. View Article : Google Scholar
|
|
32
|
Sukosd F, Kuroda N, Beothe T, Kaur AP and
Kovacs G: Deletion of chromosome 3p14.2-p25 involving the VHL and
FHIT genes in conbentional renal cell carcinoma. Cancer Res.
63:455–457. 2003.PubMed/NCBI
|
|
33
|
Jiang L, Liu X, Kolokythas A, Yu J, Wang
A, Heidbreder CE, Shi F and Zhou X: Downregulation of the Rho
GTPase signaling pathway is involved in the microRNA-138-mediated
inhibition of cell migration and invasion in tongue squamous cell
carcinoma. Int J Cancer. 127:505–512. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liu X, Wang C, Chen Z, Jin Y, Wang Y,
Kolokythas A, Dai Y and Zhou X: MicroRNA-138 suppresses
epithelial-mesenchymal transition in squamous cell carcinoma cell
lines. Biochem J. 440:23–31. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
Mir-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Young AN, Amin MB, Moreno CS, Lim SD,
Cohen C, Petros JA, Marshall FF and Neish AS: Expression profiling
of renal epithelial neoplasms: a method for tumor classification
and discovery of diagnostic molecular markers. Am J Pathol.
158:1639–1651. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Williams AA, Higgins JP, Zhao H, Ljunberg
B and Brooks JD: CD9 and vimentin distinguish clear cell from
chromophobe renal cell carcinoma. BMC Clin Pathol. 9:92009.
View Article : Google Scholar : PubMed/NCBI
|
